2 Finding the right patients – prodromal AD Alzheimers diseaseHint of subgroup in mild AD with SolenuzemabFinding the right patients – prodromal ADSelection of patients at appropriate disease stageIdentifcation of prognostic markers + using these appropriatelyEnabling simple/peripheral measurement of central effects
3 AZ TSC, joint research and the Neuroscience iMED AZ Neuroscience Innovative MedicinesCambridge USCambridge UKInternal / external partnersCRO, Consultancies. Biotech, AcademiaAZ Translational Science Centre, KIKI/AZ Joint Research Program in Translational Science11 joint research programs, in place Q [4 MUSD/yr]Centrumbildning – CNSJRC – Jan Hillert, Anna Wedell, Lars Klareskog,Hugh Salter, Lars Farde, Ina Schuppe, Magnus IvarssonSteering groupJan Andersson, Gunnar von Heijne,Sofia Hober, Britt Skogseid,Anders EkblomKI/AZ/UU/SU/KTH – SciLifeLab Research Program10 research programs, inititating Q [10 MUSD/yr]
4 AZ-KI Translational Science Centre Joint Research CommitteeKI : Profs. Anna Wedell, Lars Klareskog, Jan HillertAZ : Hugh Salter, Ina Schuppe Koistinen, Lars Farde, Magnus IvarssonJRC is quorate when cochairs or their representatives are presentBudget approvalApproval of scientific reports / agreement on achievementsConflict resolution (publications, IP)Scope and mechanism for next funding call (2015)Project governanceScientific report once per yearFinancial report once per year, yearly payment of budget to host institution – see instructions in information folder.Program co-ordinator – Ina Schuppe KoistinenAdministration – Carina Jägenstedt Bismut
5 KI-AZ Translational Science Centre Centre budgetFixed component (6 MSEK / yr) – infrastructureRent, animal facilitiesWorkshopsAttendance of postdocs/students to AZ postdoc conferencesCentral analysis staff????Research component (24 MSEK / yr) – staff + consumablesOnly 80% pre-allocated (4 yr projects, 5 yr funding)Grants to PIsWhat happens in 2015?Competitive renewal of current programsNew grant call for additional 2 year programs
6 Platforms at the Science for Life Laboratories, Stockholm A national resource centre for technology-driven bioscienceGenomics / 2nd generation sequencingProteomicssiRNA screeningBiosample immunoscreening (histo + biofluids)High-resolution microscopyChemical biologyBioinformaticsHigh content biologyfrom 2013Drug discoveryProtein productionStructural biologyGenetic models
7 AZ-KI Joint Research Program in TS : 2013 Projects Per-Johan JakobssonMedicineIdentification of sub-phenotypes and biomarkers in systemic autoimmune diseasesSven-Erik DahlénIMM, CfANew biomarker patterns for phenotyping of asthma, allergies and COPDMauro D'AmatoBioNutPost-genomic applications in IBD: exploitation of genetic information toward improved diagnosis and therapyJohan BjörkegrenMBBDNA-on/DNA-off—towards biomarkers predicting molecular disease states driving coronary artery disease in subgroups of patientsUlf AnderssonCMMDevelopment of assays to quantify HMGB1 isoform levels as biomarkers for mode of cell death and clinical prognosis in drug-induced liver injury (DILI)Henrik GrönbergMEBCirculating tumor DNA as a personalized biomarker for treatment prediction and disease monitoring in prostate and breast cancerJonas BerghOnc-PatSearch and identification of therapy predictive markers in primary and metastatic breast cancer with focus on TORC1/2 inhibition and AZD8931 with long-term goals of individual prognostication and tailored therapy selectionsJanne LehtiöOncPatImmediate adaptation analysis for prediction of efficient combination therapy with GefitinibRoman Zubarev, Agneta Nordberg, Dag AarslandDiscovery of diagnostic and prognostic biomarkers of preclinical Alzheimer’s disease by combining advanced proteomics, metabolomics and lipidomics analyses of blood plasma and cerebrospinal fluidSophie ErhardtPhyPhaThe pursuit of immune biomarkers in schizophrenia– tracking down pathophysiological mechanismsPer SvenningssonCNSBiomarkers of early Parkinson´s diseaseR&ICVGISafetyOncoNS
Your consent to our cookies if you continue to use this website.